Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FTC Calls Out Personal Injury Rx Ads As Potentially Misleading

Executive Summary

The US Federal Trade Commission says the ads may be causing patients to stop taking medications, asks that they include scientifically sound information and be careful using scare tactics.

You may also be interested in...



Metuchen Must Correct ED Drug Ads For Adult Sites After US FDA Warning Letter

Promotional campaign for Stendra (avanafil) included "adult sites" as well as the American College of Cardiology's patient-focused magazine; statements that FDA found problematic in the various ads include "get hard and stay hard" and calling the product a "next generation" PDE-5 inhibitor.

Do Consumers Understand TV Ads For Oncology Drugs?

US FDA plans to conduct a study to evaluate consumer comprehension of oncology indications in direct-to-consumer television advertising.

US FDA Should Regulate Ads Soliciting Mass Tort Suits, Group Says

Citing deaths and injuries caused when people stopped talking Xarelto in response to advertisements, US Chamber Institute for Legal Reform recommends Congress give FDA authority to halt misleading lawsuit ads.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS140894

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel